Advanced search
Publication Cover
mAbs Volume 5, 2013 - Issue 3
Submit an article Journal homepage
861
Views
11
CrossRef citations to date
0
Altmetric
Letter to the Editor

Response to: Monoclonal antibodies targeting CD20

Christian Klein Discovery Oncology; Pharma Research and Early Development (pRED); Roche Glycart AG; Schlieren, SwitzerlandCorrespondence[email protected]
,
Alfred Lammens Department of Chemistry and Biochemistry; Gene Center; Ludwig-Maximilians University Munich; Munich, Germany
,
Wolfgang Schäfer Large Molecule Research; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany
,
Guy Georges Large Molecule Research; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany
,
Manfred Schwaiger Discovery Oncology; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany
,
Ekkehard Mössner Discovery Oncology; Pharma Research and Early Development (pRED); Roche Glycart AG; Schlieren, Switzerland
,
Karl-Peter Hopfner Department of Chemistry and Biochemistry; Gene Center; Ludwig-Maximilians University Munich; Munich, Germany
,
Pablo Umaña Discovery Oncology; Pharma Research and Early Development (pRED); Roche Glycart AG; Schlieren, Switzerland
&
Gerhard Niederfellner Discovery Oncology; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany
 show all
Pages 337-338 | Received 12 Feb 2013, Accepted 12 Feb 2013, Published online: 14 Mar 2013

References

  • Mayes S, Brown N, Illidge TM. New antibody drug treatments for lymphoma. Expert Opin Biol Ther 2011; 11:623 - 40; http://dx.doi.org/10.1517/14712598.2011.560569; PMID: 21395497
  • Jain P, O'Brien S. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther 2013; 13:169 - 1822; http://dx.doi.org/10.1517/14712598.2012.735655; PMID: 23256681
  • van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010; 47:199 - 210; http://dx.doi.org/10.1053/j.seminhematol.2010.01.007; PMID: 20350667
  • Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113:1062 - 70; http://dx.doi.org/10.1182/blood-2008-07-168146; PMID: 18941114
  • Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol 2009; 27:3346 - 53; http://dx.doi.org/10.1200/JCO.2008.19.9117; PMID: 19451441
  • Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma. Haematologica 2011; 96:567 - 73; http://dx.doi.org/10.3324/haematol.2010.037390; PMID: 21173095
  • Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 402; http://dx.doi.org/10.1182/blood-2009-06-225979; PMID: 20194898
  • Salles G, Morschhauser F, Thieblemont C, Solal-Céligny P, Lamy T, Tilly H, et al. Results from a Phase I/II study (BO20999) of RO5072759 (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma. Ann Oncol 2011; 22:Abstract 66
  • Cartron G, Thieblemont C, Solal-Céligny P, Morschhauser F, Haioun C, Bouabdallah R, et al. Results from a phase II study (BO20999) of RO5072759 (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol 2011; 22 Abstract 144

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.